U.K. Pharmacovigilance Market Size, Share & Analysis Report, 2023-2032
The U.K. pharmacovigilance market size was exhibited at USD 399.44 million in 2022 and is projected to hit around USD 1,229.57 million by 2032, growing at a CAGR of 11.9% during the forecast period 2023 to 2032.
Key Takeaways:
U.K. Pharmacovigilance Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 446.97 million |
| Market Size by 2032 | USD 1,229.57 million |
| Growth Rate From 2023 to 2032 | CAGR of 11.9% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Service provider, Product life cycle, Type, Process flow, Therapeutic area, End-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Accenture; Cognizant; IBM Corporation; ArisGlobal; ICON plc.; Capgemini; IQVIA; TAKE Solutions Ltd.; PAREXEL International Corporation; BioClinica Inc. |
Rising incidence of Adverse Drug Reactions (ADRs) owing to drug abuse and the prevalence of diseases that require a combination of drugs are major growth drivers of the overall market. In addition, an upward shift in the production of new drugs and the presence of a stringent government regulatory framework for drug safety are responsible for the significant growth of the market. Advancements in the development of ADR databases and information systems have enabled reporting accurate information, which can be further utilized by research professionals for prospective clinical studies, thereby fueling the overall demand for the market. Moreover, increasing drug development activities in areas, such as personalized medicines, biosimilars, orphan drugs, companion diagnostics, along with adaptive trial designs, are projected to boost the demand for pharmacovigilance (PV) services in the coming years. According to the Royal Society of Chemistry Position Paper, U.K. had been a world spearhead in medicines discovery and research with as a minimum 10 of the top-selling drugs globally having U.K.-trained PhD organic chemists as named originators.
The pandemic is changing the way the industry is handling ongoing or upcoming clinical trials. The pandemic has accelerated the need for remote and risk-based monitoring in clinical research, which, in turn, has augmented the acceptance of virtual trial technology. This technology was deployed to speed vaccine development and helped secure full-service COVID trials and new studies. The U.K. government has adopted progressive technologies to support the processing of adverse event reports relating to COVID-19 vaccines, paying Genpact U.K. USD 2.08 million (£1.5) to develop a powerful, vaccine-specific AI tool to sift through adverse drug reactions. The pandemic has shown how these new technologies can help corporations quickly and accurately navigate complex administrative necessities, particularly amid the influx of new data. For instance, ArisGlobal, through LifeSphere MultiVigilance, offers an end-to-end safety system with production-ready automation.
The U.K. has left the European Union and the Brexit transition period came to an end in December 2020. By the end of this period, the legal framework changed, disturbing all involved parties. Starting from January 2021, the U.K. will only have one main medication regulator-the Medicines and Healthcare products Regulatory Agency (MHRA), which will retain full accountability for pharmacovigilance. In November 2020, the MHRA delivered several documents that serve as guidelines to help affected parties, particularly Marketing Authorization Holders (MAH) in the whole country, to acclimate to the future scenario.
Product Life Cycle Insights
The post-marketing or phase IV clinical trial segment led the market with a share of over 76.0% in 2022. During this phase, the safety and efficacy of the drug are analyzed on a real-time basis. In 2018, the pharmaceutical industry invested USD 7.22 billion (£5.5) in R&D in the country. The country strives to remain to be a leader in clinical research in conjunction with world-class research funders, research charities, the NHS, and global pharmaceutical businesses. Besides, the availability of market players in the country further supports the market growth. For instance, Sofpromed offers full clinical operations support to sponsors scheduling clinical trials in the country. The firm also aids pharmaceutical and biotechnology businesses around the globe to achieve rapid clinical trial start-up in the country, offering high-quality services in clinical operations, regulatory affairs, pharmacovigilance, biostatistics, data management, and drug logistics, among others.
The phase III segment is expected to witness lucrative growth over the forecast period. This phase is carried out for medicines that have conceded Phase I and II trials. These clinical trials often last a year or more and involve several thousand patients. This phase focuses on risk assessment during late-stage clinical development. In a nutshell, pharmacovigilance services have extensive applications in late Phase III clinical trial studies.
Service Provider Insights
Contract outsourcing held the largest share of over 58.0% in 2022 and is expected to witness the fastest growth during the forecast period. Contract outsourcing helps to avoid high investments and fixed overhead costs, increase resource flexibility, and secure additional capacity. Besides, high costs to uphold required levels of compliance, infrastructure, and the availability of skilled and trained in-house resources will lead to an upsurge in outsourcing trends.
An increasing number of biotechnology and pharmaceutical corporations outsourcing their PV activities to service providers, such as contract research organizations, will further drive the contract outsourcing segment. For instance, in January 2021, Dr. Reddy’s Laboratories Ltd. has chosen ArisGlobal’s LifeSphere Signal and Risk Management system for its worldwide pharmacovigilance team. ArisGlobal is present across the globe through registered offices in the U.K., France, and others.
The in-house segment is anticipated to witness moderate growth over the forecast period because this is primarily conducted by key pharmaceuticals and biotechnology companies to maintain confidentiality and ensure continuous monitoring of the process of drug development and effective data management of collected information. Companies with an extensive product pipeline and portfolio and resource availability generally adopt in-house PV. The process requires specific skill sets and an experienced workforce, especially for adverse event reporting and new product launch processes. This is expected to serve this industry with growth potential in the forthcoming years.
Type Insights
Spontaneous reporting held the largest share of over 33.9% in 2022 owing to the usability in integration with active and targeted reporting to give early safety signals of unknown medicine-related reactions. Spontaneous reporting during the post-marketing stage produces most drug safety data, yet more than clinical trials during drug development, thereby boosting demand.
Targeted spontaneous reporting is anticipated to witness the fastest growth in the forecast period. The benefits associated with it, such as better affordability, lower labor costs, and usage in routine monitoring, are expected to fuel the segment growth.
Therapeutic Area Insights
The oncology segment held the largest share of over 28.0% in 2022 and is expected to expand at the highest CAGR from 2023 to 2032. The increasing incidence of cancer resulted in accelerated R&D and clinical research. There are around 367,000 new cancer cases in the country each year, which is around 1,000 every day (2015-2017). In June 2019, Cancer Research U.K. chose Ideagen’s Q-Pulse and PleaseReview product.
The neurology segment is expected to witness significant growth during the forecast period. An increasing incidence of neurological disorders, such as epilepsy, schizophrenia, and Parkinson’s disease, resulted in the increased need for the development of new drugs with better efficacy and potency. Integrating more pharmacovigilance activities into drug development and the strategies implemented by pharmaceutical corporations further improve safety and prevent adverse events. This is eventually boosting the overall market growth.
End-use Insights
The pharmaceuticals segment held the largest share of over 43.0% in 2022. As the pharmaceutical sector expands in size as well as its reach, it faces new and more complex challenges. This particularly reflects on PV groups, which must keep up with the advances in technology, product innovation, and changing regulatory requirements while at the same time bringing their risk management responsibilities. Outsourcing pharmacovigilance proves to be a cost-effective endeavor for companies, in turn, boosting the segment growth.
The biotechnology companies segment is anticipated to witness the fastest growth over the forecast period. Drug development, right from the beginning to the finished product, is a highly complex process. It scrutinizes every aspect of the drug, thereby offering adequate safety assurance at the time of approval. However, investigative studies tend to continue after approval to further ascertain the safety of new drugs for human consumption.
Process Flow Insights
Signal detection dominated the market with a revenue share of over 38.0% in 2022. There is rising importance on signal management and signal detection in pharmacovigilance. Besides, the regulatory authority is increasingly looking for Marketing Authorization Holders to be able to establish a methodical and controlled process of signal management, thereby supporting market growth. Nowadays, Artificial Intelligence (AI) and big data are being used by companies for better assessment of signals.
The case data management segment is expected to witness the fastest growth over the forecast timeline. Nowadays, emerging technologies such as AI and machine learning are being widely used for case data management. These tools can be used to improve the reliability, quality, and availability of data by using historical information to train algorithms and offer automated insights. The U.K. National Health Service has identified massive potential savings by using analytics tools to make the maximum of its data.
Key Companies & Market Share Insights
The U.K. market is highly competitive with a considerable number of players accounting for a major revenue share. Some of the most notable market participants hold a considerable share in the market owing to their product offerings.
The market is highly fragmented with the presence of many small and large market players. This leads to high competition among market players to sustain their position. The key participants are involved in continuous product development, collaborations, partnerships, and alliances to augment market penetration. For instance, Ergomed plc publicized the acquisition of Ashfield Pharmacovigilance Inc, the U.S. operating subsidiary of UDG Healthcare plc, for a total cash consideration of $10 million. The acquisition will support the company to further develop its combined CRO and PV business worldwide, adding to the existing U.S. presence in its CRO business and offering a platform for potential growth in the North American region. Some prominent players in the U.K. pharmacovigilance market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.K. Pharmacovigilance market.
By Service Provider
By Product Life Cycle
By Type
By Process Flow
By Therapeutic Area
By End-use
Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Service Provider
1.1.2 Type
1.1.3 Product Life Cycle
1.1.4 Process Flow
1.1.5 Therapeutic area
1.1.6 End use
1.1.7 Country Scope
1.1.8 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 nova one advisor’s Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Market Definitions
1.10 Report Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 U.K. Pharmacovigilance Market Outlook, 2020 - 2032
2.3 Segment Outlook
2.4 Competitive Outlook
Chapter 3 Pharmacovigilance Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market analysis
3.1.2 Ancillary market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Pharmacovigilance Market Dynamics
3.3.1 Market driver analysis
3.3.2 Market restraint analysis
3.3.3 Industry Challenges
3.4 U.K. Pharmacovigilance Market Analysis Tools: Porters
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Value Chain Analysis
3.6.1 Pre-clinical
3.6.2 Clinical
3.6.3 PMA
3.7 Mapping of Life Cycle Against Service Offering and Their Demand
3.8 Regulatory Framework
3.9 Pharmacovigilance: Organization Structure Introduction
3.10 Pricing Models
3.10.1 Drug safety Budget Allocation by Activities
3.10.2 By Development phase
3.10.3 By Therapeutic area
3.10.4 Pricing Level
3.10.4.1 Case processing
3.10.4.2 ADR Reporting
3.10.4.3 Medical writing
3.10.4.4 Drug safety management
3.11 Technology Timeline Overview
3.11.1 Changing Technology & Adoption
3.11.1.1 Social Media
3.11.1.2 Literature screening
3.11.1.3 Automation and AI
3.11.1.4 Big data analytics in PV
Chapter 4 COVID-19 Impact Analysis
4.1 COVID-19 Outbreak
4.1.1 U.K.: COVID-19 Disease Prevalence
4.2 Current and Future Impact Analysis
4.3 Recent Developments & Strategic Outcomes
4.3.1 Regulatory requirements/changes due to Covid-19
4.3.2 Strategies implemented by companies
4.3.2.1 IQVIA
4.3.2.2 PARAXEL International Corporation
4.3.2.3 Bioclinica
4.3.2.4 Pharmaceutical Product Development (PPD)
4.3.2.5 IBM Corporation
4.3.2.6 ICON, plc
4.3.2.7 ArisGlobal
Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis
5.1 Service Provider Market Share Analysis, 2020 & 2032
5.2 Service Provider Dashboard
5.2.1 In-house
5.2.1.1 In-house market estimates and forecasts, 2020 - 2032
5.2.2 Contract Outsourcing
5.2.2.1 Contract outsourcing market estimates and forecasts, 2020 - 2032
Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis
6.1 Type Market Share Analysis, 2020 & 2032
6.2 Type Dashboard
6.2.1 Spontaneous Reporting
6.2.1.1 Spontaneous Reporting market estimates and forecasts, 2020 - 2032
6.2.2 Intensified ADR Reporting
6.2.2.1 Intensified ADR Reporting market estimates and forecasts, 2020 - 2032
6.2.3 Targeted Spontaneous Reporting
6.2.3.1 Targeted spontaneous reporting market estimates and forecasts, 2020 - 2032
6.2.4 Cohort Event Monitoring (CEM)
6.2.4.1 CEM market estimates and forecasts, 2020 - 2032
6.2.5 EHR Mining
6.2.5.1 EHR Mining market estimates and forecasts, 2020 - 2032
Chapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis
7.1 Product Life Cycle Market Share Analysis, 2020 & 2032
7.2 Product Dashboard
7.2.1 Pre-clinical
7.2.1.1 Pre-clinical market estimates and forecasts, 2020 - 2032
7.2.2 Phase I
7.2.2.1 Phase I market estimates and forecasts, 2020 - 2032
7.2.3 Phase II
7.2.3.1 Phase II market estimates and forecasts, 2020 - 2032
7.2.4 Phase III
7.2.4.1 Phase III market estimates and forecasts, 2020 - 2032
7.2.5 Phase IV
7.2.5.1 Phase IV market estimates and forecasts, 2020 - 2032
Chapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis
8.1 Process Flow Market Share Analysis, 2020 & 2032
8.2 Process Flow Dashboard
8.2.1 Case data management
8.2.1.1 Case data management market estimates and forecasts, 2020 - 2032
8.2.1.2 Case logging
8.2.1.3 Case logging market estimates and forecasts, 2020 - 2032
8.2.1.4 Case data analysis
8.2.1.5 Case data analysis market estimates and forecasts, 2020 - 2032
8.2.1.6 Medical reviewing and reporting
8.2.1.7 Medical reviewing and reporting market estimates and forecasts, 2020 - 2032
8.2.2 Signal detection
8.2.2.1 Signal detection market estimates and forecasts, 2020 - 2032
8.2.2.2 Adverse Event Logging
8.2.2.3 Adverse Event Logging market estimates and forecasts, 2020 - 2032
8.2.2.4 Adverse Event Analysis
8.2.2.5 Adverse Event Analysis market estimates and forecasts, 2020 - 2032
8.2.2.6 Adverse Event Review & Reporting
8.2.2.7 Adverse Event Review & Reporting market estimates and forecasts, 2020 - 2032
8.2.3 Risk Management System
8.2.3.1 Risk Management System market estimates and forecasts, 2020 - 2032
8.2.3.2 Risk Evaluation System
8.2.3.3 Risk Evaluation System market estimates and forecasts, 2020 - 2032
8.2.3.4 Risk Mitigation System
8.2.3.5 Risk Mitigation System market estimates and forecasts, 2020 - 2032
Chapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis
9.1 Therapeutic Area Market Share Analysis, 2020 & 2032
9.2 Therapeutic Area Dashboard
9.2.1 Oncology
9.2.1.1 Oncology market estimates and forecasts, 2020 - 2032
9.2.2 Neurology
9.2.2.1 Neurology market estimates and forecasts, 2020 - 2032
9.2.3 Cardiology
9.2.3.1 Cardiology market estimates and forecasts, 2020 - 2032
9.2.4 Respiratory systems
9.2.4.1 Respiratory systems market estimates and forecasts, 2020 - 2032
9.2.5 Others
9.2.5.1 Others market estimates and forecasts, 2020 - 2032
Chapter 10 Pharmacovigilance Market: End-use Estimates & Trend Analysis
10.1 End-use Market Share Analysis, 2020 & 2032
10.2 End-use Dashboard
10.2.1 Pharmaceuticals
10.2.1.1 Pharmaceuticals market estimates and forecasts, 2020 - 2032
10.2.2 Biotechnology Companies
10.2.2.1 Biotechnology companies market estimates and forecasts, 2020 - 2032
10.2.3 Medical Device Manufacturers
10.2.3.1 Medical Device Manufacturers market estimates and forecasts, 2020 - 2032
10.2.4 Others
10.2.4.1 Others market estimates and forecasts, 2020 - 2032
Chapter 11 Competitive Outlook
11.1 Market Participation Categorization
11.2 Public Companies
11.2.1 Company market position analysis
11.2.2 Consolidation Trends
11.3 Private Companies
11.3.1 List of key emerging companies
Chapter 12 Company Profiles
12.1 Accenture
12.1.1 Company overview
12.1.2 Service benchmarking
12.1.3 Organization structure & Team Composition
12.1.3.1 Team composition
12.1.4 Financial performance
12.1.5 R&D expenditure
12.1.6 Strategic initiatives
12.1.7 SWOT Analysis
12.2 IQVIA
12.2.1 Company overview
12.2.2 Service benchmarking
12.2.3 Organization structure & Team Composition
12.2.3.1 Team composition
12.2.4 Financial performance
12.2.5 Strategic initiatives
12.2.6 SWOT Analysis
12.33 Cognizant
12.3.1 Company overview
12.3.2 Service benchmarking
12.3.3 Organization structure & Team Composition
12.3.3.1 Team composition
12.3.4 Financial performance
12.3.5 Strategic initiatives
12.3.6 SWOT Analysis
12.4 IBM Corporation
12.4.1 Company overview
12.4.2 Service benchmarking
12.4.3 Organization structure & Team Composition
12.4.3.1 Team composition
12.4.4 Financial performance
12.4.5 R&D expenditure
12.4.6 Strategic initiatives
12.4.7 SWOT Analysis
12.5 ArisGlobal
12.5.1 Company overview
12.5.2 Service benchmarking
12.5.3 Organization structure & Team Composition
12.5.3.1 Team composition
12.5.4 Financial performance
12.5.5 Strategic initiatives
12.5.6 SWOT Analysis
12.6 ICON Plc.
12.6.1 Company overview
12.6.2 Service benchmarking
12.6.3 Organization structure & Team Composition
12.6.3.1 Team composition
12.6.4 Financial performance
12.6.5 Strategic initiatives
12.6.6 SWOT Analysis
12.7 Capgemini
12.7.1 Company overview
12.7.2 Service benchmarking
12.7.3 Organization structure & Team Composition
12.7.3.1 Team composition
12.7.4 Financial performance
12.7.5 Strategic initiatives
12.7.6 SWOT Analysis
12.8 TAKE Solutions
12.8.1 Company overview
12.8.2 Service benchmarking
12.8.3 Organization structure & Team Composition
12.8.3.1 Team composition
12.8.4 Financial performance
12.8.5 Strategic initiatives
12.8.6 SWOT Analysis
12.9 PAREXEL International Corporation
12.9.1 Company overview
12.9.2 Service benchmarking
12.9.3 Organization structure & Team Composition
12.9.3.1 Team composition
12.9.4 Financial performance
12.9.5 Strategic initiatives
12.9.6 SWOT Analysis
12.10 BioClinica, Inc.
12.10.1 Company overview
12.10.2 Service benchmarking
12.10.3 Organization structure & Team Composition
12.10.3.1 Team composition
12.10.4 Financial performance
12.10.5 Strategic initiatives
12.10.6 SWOT Analysis
Chapter 13 Winning Strategies
13.1 Key Winning/Scoring Criteria’s
13.1.1 By categories
13.1.1.1 Pharmaceuticals
13.1.1.2 Biotech companies
13.1.1.3 Medical device companies
13.2 Key Vendor Selection Factors
13.2.1 By Category
13.2.2 BY Company size
13.2.2.1 KEY TAKEAWAYS
13.3 Switching Cost Analysis
13.4 Detailed List of Companies
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers